期刊文献+
共找到49篇文章
< 1 2 3 >
每页显示 20 50 100
Pharmacokinetics of nifedipine sustained-release tablets in healthy Chinese volunteers 被引量:3
1
作者 武静 王本杰 +2 位作者 魏春敏 卜凡龙 郭瑞臣 《Journal of Chinese Pharmaceutical Sciences》 CAS 2007年第3期192-196,共5页
Aim To establish a LC-MS method for determining the concentration of nifedipine in human plasma and to evaluate the pharmacokinetic characteristics of nifedipine sustained-release tablets. Methods A XB-C18 (5 μm, 4.... Aim To establish a LC-MS method for determining the concentration of nifedipine in human plasma and to evaluate the pharmacokinetic characteristics of nifedipine sustained-release tablets. Methods A XB-C18 (5 μm, 4.6 mm ×150 mm) column and a mobile phase of methanol: 0.01 mol·L^-1ammonium acetate (60:40, V/V) were used to separate nifedipine, the detections was accuracy under atmosperic pressure electronic spray ionization (AP-ESI) mode and ion mass spectrum (m/z) of 314.9 [M+H]^+ for nifedipine, and 320.8 [M+H]^+ for lorazepam (Internal Standard, IS). Results The linear range of nifedipine was 0.3 - 80 ng·mL^-1 ( r = 0.9997), and the limit of quantitation (LOQ) was 0.3 ng·mL^-1. The nifedipine pharmacokinetic parameters after a single dose of 20 mg nifedipine sustained-release tablets test (T) or reference (R) were as the followings, t1/2 (6.73 ± 2.00) h and (7.04 ± 2.18) h, Tmax (4.28 ± 0.70) h and (4.48 ± 0.70) h, Cmax(39.66 ± 10.58) ng·mL^-1 and (40.19 ± 10.97) ng·mL^-1, AUC0-36 (391.63 ± 108.55) ng·mL^-1·h and (387.57 ± 121.51) ng·mL^-1·h, and AUC0-∞ (408.28 ± 121.16) ng·mL^-1·h and (406.15 ± 133.13) ng·mL^-1·h. The relative bioavailability of nifedipine sustained-release tablets (test) was (103.02 ± 13.93) %. Conclusion LC-MS method for the determination of concentrations of nifedipine in human plasma was sensitive and accurate, and could be used in nifedipine bioavailability and pharmacokinetic studies. 展开更多
关键词 Nifedipine sustained-release tablets LC-MS PHARMACOKINETICS BIOEQUIVALENCE
下载PDF
Preparation and <i>in Vitro</i>Drug Release Evaluation of Once-Daily Metformin Hydrochloride Sustained-Release Tablets 被引量:1
2
作者 Ling Zhao Yumeng Wei +4 位作者 Yong Mei Li Yang Yuan You Xufeng Yang Yanhong Jiang 《Pharmacology & Pharmacy》 2012年第4期468-473,共6页
The objective of this study was to develop once-daily metformin hydrochloride sustained-release tablets (MHSRT) and evaluate their in vitro release behavior. MHSRT were prepared by the film coating method. The in vitr... The objective of this study was to develop once-daily metformin hydrochloride sustained-release tablets (MHSRT) and evaluate their in vitro release behavior. MHSRT were prepared by the film coating method. The in vitro drug release rate of MHSRT and the commercial tablets Fortamet? made in the United States of America in water was fitted with zero order kinetic equation, and Ritger-Peppas kinetic equation in 0.1 M HCl and pH 6.8-phosphate buffer, respectively. The similarity factor f2 values of MHSRT in three different dissolution medium were 82, 80 and 74, respectively in comparison with imported Fortamet?, which were all greater than 50. The results of storage-stability showed that MHSRT were stable for at least 6 months under stress condition (40℃ ± 2℃, RH 75% ± 5%). Therefore, in this study, MHSRT were successfully prepared using optimized formulation technologies that meet mass produce. The in vitro release behavior of MHSRT was almost similar to that of imported Fortamet?. 展开更多
关键词 sustained-release tablets METFORMIN HYDROCHLORIDE In Vitro Release Rate Similarity Factor Kinetic Model
下载PDF
Preparation and evaluation of sustained-release azithromycin tablets in vitro and in vivo
3
作者 Le Sun Weixiang Zhang +1 位作者 Xiaohong Liu Jin Sun 《Asian Journal of Pharmaceutical Sciences》 SCIE CAS 2014年第3期155-161,共7页
The objective of this study was to prepare azithromycin(AZI)sustained-release products in order to allow for a high dose to be administered,reduce gastrointestinal side-effects and increase the compliance of patients.... The objective of this study was to prepare azithromycin(AZI)sustained-release products in order to allow for a high dose to be administered,reduce gastrointestinal side-effects and increase the compliance of patients.AZI sustained-release tablets with different release performance(F-I:T_(100%)=3 h and F-II:T_(100%)=8 h in pH 6.0 phosphate buffer)were successfully prepared by wet granulation.The in vitro release rate and drug release mechanism were studied.The release rate of F-Iwas affected by dissolutionmedia with different pH,but not for F-II.HixsoneCrowellmodel was the best regression fitting model for F-I and F-II.Additionally,F-I and F-II both belonged to non-Fick diffusion.Oral pharmacokinetics of the two tablets and one AZI dispersible tablet as reference were studied in six healthy beagle dogs after oral administration.Compared with the reference,the C_(max) of F-I and F-II were decreased,and the T_(max) were prolonged,in that case which meet the requirement of sustained-release tablets.The relative bioavailability of F-I and F-II were 79.12%and 64.09%.T-test ofAUC_(0-144),and AUC_(0-∞) for F-I and F-II indicated there was no significant difference between F-I and F-II.These mean that the extended release rate did not induce different pharmacokinetics in vivo. 展开更多
关键词 AZITHROMYCIN sustained-release tablet PHARMACOKINETICS UPLC-MS-MS
下载PDF
Clinical observation of Baitou Weng Decoction combined with mesalazine sustained-release tablets in treating heat-toxic and smoldering ulcerative colitis
4
作者 Qian-Zhang Ma Yun Li Yuan-Quan Ding 《Journal of Hainan Medical University》 2019年第12期37-42,共6页
Objective:To observe the clinical efficacy of Baitou Weng Decoction combined with mesalazine sustained-release tablets in the treatment of ulcerative colitis with febrile heat and its effect on immune function and ser... Objective:To observe the clinical efficacy of Baitou Weng Decoction combined with mesalazine sustained-release tablets in the treatment of ulcerative colitis with febrile heat and its effect on immune function and serum inflammatory factors.Methods: A total of 84 patients with ulcerative colitis were randomly divided into control group and treatment group, with 42 cases in each group. The control group was given mesalazine sustained-release tablets orally, while the treatment group was given Baitou Weng Decoction and mesalazine sustained-release tablets orally. The treatment period was 30 days and the patients were followed up for 3 months. After treatment, the clinical efficacy, quality of life, immune function and serum inflammatory factors of the two groups were observed.Results: The effective rate of treatment group (90.47%) was higher than that of control group (73.81%) (P<0.05);compared with before treatment, the scores of inflammatory bowel disease quality of life questionnaire scale in both groups were significantly improved (P<0.05), and the difference between the two groups was significant (P<0.05);after treatment, the plasma CD4+/CD8+ ratio and NK+ levels in both groups were significantly higher than those before treatment (P<0.05), and the treatment group was changed. The serum levels of tumor necrosis factor-α, interleukin-17 and interleukin-23 were significantly decreased in both groups after treatment (P<0.05), and the improvement was more significant in the treatment group (P<0.05). No significant adverse reactions were observed in the treatment group.Conclusions: Modified Baitou Weng Decoction combined with mesalazine in the treatment of heat-toxic and incandescent ulcerative colitis can significantly improve the clinical efficacy, improve the quality of life of patients, effectively regulate the expression level of serum inflammatory factors in ulcerative colitis patients, promote the recovery of patients' immune function, and have high drug safety. 展开更多
关键词 Baitou WENG DECOCTION MESALAZINE sustained-release tablets Hot toxicity ULCERATIVE colitis Immune function Serum inflammatory factor
下载PDF
Clinical observation on treatment of cancer pain with TCM oriented drugs combined with oxycodone sustained-release tablets and nimesulide sustained-release tablets
5
作者 Feng-Jiao He Ke-Xiong Li +2 位作者 Pu-Hua Zeng Hai-Yan Yi Xiao-Lan Jian 《TMR Cancer》 2018年第4期118-123,共6页
Objective: To study the effect of the transdermal preparation of traditional Chinese medicine in treating cancer pain. Methods: From October 2016 to January 2018, 126 patients with cancer pain were enrolled and divi... Objective: To study the effect of the transdermal preparation of traditional Chinese medicine in treating cancer pain. Methods: From October 2016 to January 2018, 126 patients with cancer pain were enrolled and divided into 4 groups, 39 patients in group A (directed TCM permeation), 26 patients in group B (oxycodone sustained-release tablets), 32 patients in group C (Chinese medicine directed drug penetration + oxycodone sustained-release tablets), and 29 patients group D (Chinese medicine directed drug penetration + oxycodone sustained-release tablets + nimesulide sustained release tablets), according to KPS scores. Results: Transdermal preparations of traditional Chinese medicine can significantly alleviate cancer pain. For the treatment of moderate to severe cancer pain, the Chinese medicine transdermal preparation can reduce the dosage of oxycodone sustained-release tablets. At the same time, the patient's KPS and NRS scores were significantly reduced. Moreover, the transdermal preparation of traditional Chinese medicine has a better therapeutic effect on visceral pain. Conclusion: The traditional Chinese medicine tra_nsdermal preparation combined with western medicine for the treatment of cancer pain may be a new method for the treatment of cancer pain. 展开更多
关键词 Chinese medicine directed drug Oxycodone sustained-release tablets Cancer pain Clinical efficacy
下载PDF
Pharmacokinetic Study on Lovastatin Sustained-release Tablet and Sustained-release Capsule in Begal Dogs
6
作者 付琳 代宗顺 +1 位作者 侯淑贤 万元胜 《Journal of Huazhong University of Science and Technology(Medical Sciences)》 SCIE CAS 2004年第2期116-119,共4页
This study pharmacokinetically examined the lovastatin sustained-release tablet and sustained-release capsule in Beagle dogs. An reversed-phase HPLC method was established for the determination of lovastatin in Beagl... This study pharmacokinetically examined the lovastatin sustained-release tablet and sustained-release capsule in Beagle dogs. An reversed-phase HPLC method was established for the determination of lovastatin in Beagle dog plasma. Pharmacokinetic findings were compared among three preparation(lovastatin sustained-release tablet,T p; sustained-release capsule,T J and conventional capsule). Our results showed that the pharmacokinetic parameters in 6 dogs after single-dose oral administration of three perparations were calculated. T max, C max and MRT revealed significant difference (P<0.05). Relative bioavailability was 111.5±16.9 % (T P) and 110.4%±9.6 % (T J). The pharmacokinetic parameters in the 6 dogs after multiple-dose oral administration of three perparations, T max, C max MRT and DF had significant difference (P<0.05); C av , C min and AUC 0-24 h displayed no significant difference (P>0.05). It is concluded that the lovastatin sustained-release tablet and sustained-release capsule are able to maintain a sustained-release for 24 h. 展开更多
关键词 LOVASTATIN sustained-release tablets sustained-release capsules PHARMACOKINETIC SINGLE-DOSE MULTIPLE-DOSE
下载PDF
Simultaneous Analysis of Indapamide and Related Impurities in Sustained-Release Tablets by a Single-Run HPLC-PDA Method
7
作者 YAO Wu ZHOU Shiwen CHENG Qiongru 《Wuhan University Journal of Natural Sciences》 CAS CSCD 2023年第4期333-340,共8页
The contents of indapamide and related impurities in generic indapamide sustained-release tablets were simultaneously detected by a single-run high performance liquid chromatography equipped with photodiode array dete... The contents of indapamide and related impurities in generic indapamide sustained-release tablets were simultaneously detected by a single-run high performance liquid chromatography equipped with photodiode array detector(HPLC-PDA)method for the quality control in this paper.The results showed the method had a good selectivity and was validated through linearity,limits of detection and quantification,recovery,and precision.The linear ranges of indapamide,2-methyl-1-nitroso-2,3-dihydro-1H-indole(impurity A,ImA),4-chloro-N-(2-methyl-1H-indol-1-yl)-3-sulphamoyl-benzamide(impurity B,ImB)and 4-chloro-3-sulfamoylbenzoic acid(impurity 1,Im1)were 0.028-1.80μg/mL(R=0.99995),0.060-1.20μg/mL(R=0.9996),0.0324-1.20μg/mL(R=0.99985)and 0.060-1.20μg/mL(R=0.9997)with detection limits of 0.0093,0.012,0.012 and 0.006μg/mL,respectively.ImA and Im1 were not detectable in the generic drug.The content of indapamide was 96.7%of the labeled amount with a relative standard deviation(RSD)of 1.30%,and the percentage of ImB relative to the labeled amounts of indapamide was 0.106%with an RSD of 1.82%.The content of other unspecified impurities all met the reference quality standards.The results provided references for the quality control and the quality standard study of generic indapamide sustained-release tablets. 展开更多
关键词 INDAPAMIDE related impurity sustained-release tablets high performance liquid chromatography equipped with photodiode array detector(HPLC-PDA)
原文传递
Qualitative and quantitative analysis of HPLC fingerprint of Wuji gastric floating sustained-release tablets 被引量:1
8
作者 陈中芬 刘文 +2 位作者 陈大业 施晓伟 王群 《Journal of Chinese Pharmaceutical Sciences》 CAS CSCD 2015年第5期310-317,共8页
A qualitative and quantitative test method of fingerprint of Wuji gastric floating sustained-release tablets was established. High performance liquid chromatography (HPLC) was adopted, using Agilent ZORBAX SB-C18 co... A qualitative and quantitative test method of fingerprint of Wuji gastric floating sustained-release tablets was established. High performance liquid chromatography (HPLC) was adopted, using Agilent ZORBAX SB-C18 column (250 mm×4.6 mm, 5 μm) as the chromatographic column, and acetonitrile-0.05 mol/L potassium dihydrogen phosphate solution as the mobile phase in a gradient elution with the flow rate of 1.0 mL/min. Sample solution (10 μL) was injected and was tested at the wavelength of 225 nm for 75 min at the column temperature of 30 ℃, Fingerprint similarity software (2004A version) was used to conduct data analysis. A total of 11 batches of Wuji gastric floating sustained-release tablets were tested and analyzed with HPLC fingerprint. Seventeen common peaks were found and the similarity of the 11 batches of agents was greater than 0.9, indicating that the production process of the agent is stable and feasible. The method is operable and could effectively control the quality of Wuji gastric floating sustained-release tablets. 展开更多
关键词 FINGERPRINT HPLC Wuji gastric floating sustained-release tablets
原文传递
左乙拉西坦片仿制药与原研药治疗儿童癫痫的疗效、安全性比较
9
作者 颜颖慧 王凤娇 +1 位作者 王文娟 朱增燕 《中国医院用药评价与分析》 2024年第1期62-65,70,共5页
目的:研究住院环境下儿童癫痫患者使用左乙拉西坦片仿制药与原研药以及在两者之间切换使用的临床结果,探讨门诊环境下左乙拉西坦片原研药的转换与回切。方法:对2020年1月至2022年6月于该院住院并接受左乙拉西坦片250 mg治疗的125例儿童... 目的:研究住院环境下儿童癫痫患者使用左乙拉西坦片仿制药与原研药以及在两者之间切换使用的临床结果,探讨门诊环境下左乙拉西坦片原研药的转换与回切。方法:对2020年1月至2022年6月于该院住院并接受左乙拉西坦片250 mg治疗的125例儿童癫痫患者进行回顾性队列研究。计算使用仿制药及原研药患者的发作频率减少率,汇总并分析在两个品种间切换的患者的特征,并进一步随访原研药在门诊的转换与回切率。结果:125例癫痫患者中,原研药组患者的癫痫控制率为87.50%(63/72),仿制药组为83.02%(44/53),两组的差异无统计学意义(P>0.05);患者联合用药数量增加将降低癫痫控制率(OR=0.333,95%CI=0.114~0.969,P=0.044)。报告的4例不良反应均来自原研药组单药治疗的患者,分别为情绪不稳(2例)、皮疹(2例)。入组患者中,14例存在原研及仿制药品种间切换的情况,在控制性别、年龄及治疗特征时,患者入院次数(OR=2.7,95%CI=1.506~4.791,P=0.001)、癫痫控制情况(OR=0.07,95%CI=0.009~0.555,P=0.012)与品种切换相关。门诊随访过程中,原研药的累积转换率为50.05%,校正累积回切率为20.29%。结论:本研究队列中,原研与仿制左乙拉西坦片对癫痫儿童的疗效和安全性无差异,药物品种的切换更多出现在入院次数增加和癫痫未控制的情况下。尽管仿制药物已在门诊普及,原研药物仍存在固定的使用人群。 展开更多
关键词 原研药 仿制药 左乙拉西坦片 儿童癫痫 疗效 安全性
下载PDF
左乙拉西坦片联合维生素B_(12)片治疗儿童癫痫的临床研究 被引量:1
10
作者 全小宁 楚乐 孙小春 《中国医药》 2024年第2期217-220,共4页
目的 探讨左乙拉西坦片联合维生素B_(12)片对儿童癫痫的治疗效果。方法 选取2020年1月至2022年8月在三二〇一医院接受治疗的癫痫患儿88例,将其按随机数字表法分为对照组(n=44)和观察组(n=44)。对照组患儿采用左乙拉西坦片进行治疗,观察... 目的 探讨左乙拉西坦片联合维生素B_(12)片对儿童癫痫的治疗效果。方法 选取2020年1月至2022年8月在三二〇一医院接受治疗的癫痫患儿88例,将其按随机数字表法分为对照组(n=44)和观察组(n=44)。对照组患儿采用左乙拉西坦片进行治疗,观察组患儿采用左乙拉西坦片联合维生素B_(12)片进行治疗。治疗6个月后比较2组的总有效率,治疗前后癫痫发作频率、每次发作持续时间以及血清同型半胱氨酸(Hcy)、S-100β、神经元特异性烯醇化酶(NSE)水平和不良反应发生情况。结果 观察组的总有效率高于对照组[90.9%(40/44)比75.0%(33/44)],差异有统计学意义(P=0.047)。与治疗前比较,2组患儿治疗后癫痫发作频率均明显降低,每次发作持续时间均明显减少,且观察组癫痫发作频率低于、每次发作时间少于对照组(均P<0.05)。2组患儿治疗后血清Hcy水平明显高于治疗前、血清S-100β以及NSE水平均明显低于治疗前,且观察组血清Hcy、S-100β以及NSE水平均低于对照组(均P<0.05)。2组总不良反应发生率比较,差异无统计学意义(P=0.437)。结论 左乙拉西坦片联合维生素B_(12)片治疗儿童癫痫安全有效,可作为临床治疗癫痫患儿的有效手段。 展开更多
关键词 癫痫 左乙拉西坦片 维生素B_(12)片
下载PDF
左乙拉西坦片与卡马西平片治疗难治性癫痫的效果 被引量:1
11
作者 党治兰 樊鹏妮 《临床医学研究与实践》 2024年第14期62-65,74,共5页
目的分析难治性癫痫患者采取左乙拉西坦片与卡马西平片口服治疗对临床症状的缓解效果。方法将我院2020年1月至2021年12月收治的100例难治性癫痫患者为研究对象,以随机法将其分为卡马西平片组(50例,卡马西平片口服治疗)和左乙拉西坦片组... 目的分析难治性癫痫患者采取左乙拉西坦片与卡马西平片口服治疗对临床症状的缓解效果。方法将我院2020年1月至2021年12月收治的100例难治性癫痫患者为研究对象,以随机法将其分为卡马西平片组(50例,卡马西平片口服治疗)和左乙拉西坦片组(50例,左乙拉西坦片口服治疗)。比较两组的治疗效果。结果左乙拉西坦片组的治疗总有效率显著高于卡马西平片组(P<0.05)。治疗前,两组的癫痫发作频率、持续时间及脑电频率无明显差异(P>0.05);治疗后,左乙拉西坦片组的癫痫发作频率、持续时间及脑电频率θ、δ显著低于卡马西平片组,脑电频率α显著高于卡马西平片组(P<0.05)。治疗前,两组的免疫球蛋白A(IgA)、免疫球蛋白G(IgG)及免疫球蛋白M(IgM)水平无明显差异(P>0.05);治疗后,左乙拉西坦片组的IgA、IgG及IgM水平显著高于卡马西平片组(P<0.05)。治疗前,两组的S-100β蛋白、髓鞘碱性蛋白(MBP)、神经元特异性烯醇化酶(NSE)及脑源性神经营养因子(BDNF)水平无明显差异(P>0.05);治疗后,左乙拉西坦片组的S-100β蛋白、MBP及NSE水平显著低于卡马西平片组,BDNF水平显著高于卡马西平片组(P<0.05)。左乙拉西坦片组的药副反应总发生率显著低于卡马西平片组(P<0.05)。结论左乙拉西坦片治疗难治性癫痫患者具有更高的临床应用价值。 展开更多
关键词 难治性癫痫 左乙拉西坦片 卡马西平片
下载PDF
经颅磁刺激分别联合左乙拉西坦片和卡马西平片治疗癫痫的效果及对血清Nesfatin-1、S100B、BDNF水平的影响
12
作者 张鹏飞 张会平 张金龙 《临床医学研究与实践》 2024年第18期25-28,共4页
目的探讨经颅磁刺激分别联合左乙拉西坦片和卡马西平片治疗癫痫的效果及对血清摄食抑制因子-1(Nesfatin-1)、S100钙结合蛋白B(S100B)、脑源性神经营养因子(BDNF)水平的影响。方法根据随机数字表法将2018年2月至2022年2月接受治疗的80例... 目的探讨经颅磁刺激分别联合左乙拉西坦片和卡马西平片治疗癫痫的效果及对血清摄食抑制因子-1(Nesfatin-1)、S100钙结合蛋白B(S100B)、脑源性神经营养因子(BDNF)水平的影响。方法根据随机数字表法将2018年2月至2022年2月接受治疗的80例癫痫患者分为研究组(n=40)和对照组(n=40)。两组均进行经颅磁刺激治疗,在此基础上,研究组给予左乙拉西坦片治疗,对照组给予卡马西平片治疗。比较两组的临床效果。结果研究组的治疗总有效率高于对照组(P<0.05)。治疗后,两组的认知功能评分均升高,且研究组高于对照组(P<0.05)。治疗后,两组的Nesfatin-1、S100B水平降低,BDNF水平升高,且研究组优于对照组(P<0.05)。治疗后,两组的癫痫患者生活质量量表(QOLIE-31)各维度评分均升高,且研究组高于对照组(P<0.05)。两组的不良反应总发生率无显著差异(P>0.05)。结论经颅磁刺激联合左乙拉西坦片治疗癫痫的效果显著,可提高认知功能,促进血清Nesfatin-1、S100B水平降低和BDNF水平升高,安全性高。 展开更多
关键词 经颅磁刺激 癫痫 左乙拉西坦片 卡马西平片
下载PDF
左乙拉西坦片联合奥卡西平片治疗癫痫患者的疗效及对血清miR-222、BAFF水平的影响 被引量:11
13
作者 席光明 陈召东 《海南医学》 CAS 2023年第3期318-321,共4页
目的观察左乙拉西坦片联合奥卡西平片治疗癫痫患者的疗效,探讨其对患者血清微小核糖核酸-222(miR-222)、B细胞活化因子(BAFF)水平的影响。方法选择2019年11月至2021年11月商洛市中心医院神经内科接诊的80例癫痫患者进行研究,按照随机数... 目的观察左乙拉西坦片联合奥卡西平片治疗癫痫患者的疗效,探讨其对患者血清微小核糖核酸-222(miR-222)、B细胞活化因子(BAFF)水平的影响。方法选择2019年11月至2021年11月商洛市中心医院神经内科接诊的80例癫痫患者进行研究,按照随机数表法分为对照组和观察组各40例。对照组患者给予奥卡西平片治疗,观察组患者给予左乙拉西坦片联合奥卡西平片治疗,两组患者均持续治疗3个月。比较两组患者治疗后的疗效,以及治疗前后的血清miR-222、BAFF水平、神经功能指标和不良反应发生情况。结果观察组患者的治疗总有效率为95.00%,明显高于对照组的77.50%,差异有统计学意义(P<0.05);治疗前,两组患者的miR-222、BAFF水平比较差异均无统计学意义(P>0.05);治疗3个月后,观察组患者的miR-222、BAFF水平分别为0.87±0.16、(4.96±0.97)ng/mL,明显低于对照组的1.19±0.21、(7.49±2.04)ng/mL,差异均有统计学意义(P<0.05);治疗前,两组患者的S-100β蛋白(S-100β)、神经元特异性烯醇化酶(NES)、胶质纤维酸性蛋白(GFAP)水平比较差异均无统计学意义(P>0.05);治疗3个月后,观察组患者的S-100β、NES、GFAP水平分别为(0.41±0.03)μg/L、(10.01±2.12)ng/mL、(2.54±0.21)ng/L,明显低于对照组的(0.53±0.04)μg/L、(15.03±2.16)ng/mL、(3.21±0.14)ng/L,差异均有统计学意义(P<0.05);两组患者的不良反应总发生率比较差异无统计学意义(P>0.05)。结论左乙拉西坦片联合奥卡西平片治疗癫痫可改善患者的血清miR-222、BAFF水平,治疗效果显著,具有临床应用价值。 展开更多
关键词 癫痫 左乙拉西坦片 奥卡西平片 疗效 血清微小核糖核酸-222 B细胞活化因子
下载PDF
左乙拉西坦片联合奥卡西平片治疗癫痫的疗效及对患者血清miR-222、BAFF水平的影响 被引量:7
14
作者 康乐乐 苗婵婵 高海茸 《海南医学》 CAS 2023年第5期625-628,共4页
目的探讨左乙拉西坦片联合奥卡西平片治疗癫痫的疗效及对患者血清微小核糖核酸-222(miR-222)、B细胞活化因子(BAFF)水平的影响。方法选择2019年2月至2021年10月延安大学附属医院收治的106例癫痫患者进行前瞻性研究,按照随机数表法分为... 目的探讨左乙拉西坦片联合奥卡西平片治疗癫痫的疗效及对患者血清微小核糖核酸-222(miR-222)、B细胞活化因子(BAFF)水平的影响。方法选择2019年2月至2021年10月延安大学附属医院收治的106例癫痫患者进行前瞻性研究,按照随机数表法分为观察组和对照组各53例。对照组患者给予奥卡西平片治疗,观察组患者在对照组基础上联合左乙拉西坦片治疗,两组患者均持续治疗6个月。比较两组患者治疗后的临床疗效,治疗前后的血清miR-222、BAFF水平、痫样放电数量、累及导联数、蒙特利尔认知量表(MoCA)评分以及治疗期间的不良反应发生情况。结果治疗后,观察组患者的临床疗效总有效率为94.34%,明显高于对照组的77.36%,差异有统计学意义(P<0.05);治疗后,观察组患者的血清miR-222、BAFF水平分别为0.86±0.15、(5.21±0.87)ng/mL,明显低于对照组的1.03±0.12、(6.89±1.11)ng/mL,差异均有统计学意义(P<0.05);治疗后,观察组患者的痫样放电、累及导联数分别为(9.84±1.67)t/180 s、(4.63±0.77)t/180 s,明显低于对照组的(12.17±1.83)t/180 s、(5.85±0.92)t/180 s,MoCA评分为(27.24±1.52)分,明显高于对照组的(26.38±1.30)分,差异均有统计学意义(P<0.05);治疗期间,观察组和对照组患者的不良反应总发生率分别为15.09%和11.32%,差异无统计学意义(P>0.05)。结论左乙拉西坦片联合奥卡西平片可明显提高癫痫患者的治疗效果,且能降低血清miR-222、BAFF的表达水平,具有临床推广应用价值。 展开更多
关键词 癫痫 奥卡西平片 左乙拉西坦片 微小核糖核酸-222 B细胞活化因子 脑电图 认知功能
下载PDF
左乙拉西坦缓释片制备工艺研究
15
作者 杨鑫 杨广德 +1 位作者 张继业 徐晶 《中国药业》 CAS 2023年第2期39-42,共4页
目的建立简单易行、符合大生产要求的左乙拉西坦缓释片的制备工艺。方法通过对自制左乙拉西坦缓释片处方中粘合剂、缓释材料,以及对制备工艺中制片方法、筛网大小、压片压力的筛选,优化该缓释片的处方及制备工艺。通过硬度、质量差异、... 目的建立简单易行、符合大生产要求的左乙拉西坦缓释片的制备工艺。方法通过对自制左乙拉西坦缓释片处方中粘合剂、缓释材料,以及对制备工艺中制片方法、筛网大小、压片压力的筛选,优化该缓释片的处方及制备工艺。通过硬度、质量差异、脆碎度、含量,以及溶出均一性、稳定性试验等对中试样品片剂进行质量评价。结果自制左乙拉西坦缓释片以羟丙甲基纤维素为骨架材料、与Keppra XRTM的释药行为相似,其硬度、溶出效果与原研片无显著差异,其质量差异、脆碎度检查,以及溶出均一性、稳定性试验结果符合2015年版《中国药典(二部)》中的相关规定。结论建立的左乙拉西坦缓释片制备工艺可行。 展开更多
关键词 左乙拉西坦缓释片 处方筛选 工艺研究 质量标准 药品一致性评价
下载PDF
左乙拉西坦联合双歧杆菌乳杆菌三联活菌片对癫痫患儿认知功能和细胞免疫的影响
16
作者 赵萍 代锦文 《中国药物与临床》 CAS 2023年第10期652-655,共4页
目的分析癫痫患儿采用左乙拉西坦联合双歧杆菌乳杆菌三联活菌片治疗的临床效果及对患儿认知功能和细胞免疫的影响,以期为临床治疗癫痫患儿提供依据。方法将河南省南阳市中心医院2022年6月至2023年3月收治的105例癫痫患儿根据用药不同分... 目的分析癫痫患儿采用左乙拉西坦联合双歧杆菌乳杆菌三联活菌片治疗的临床效果及对患儿认知功能和细胞免疫的影响,以期为临床治疗癫痫患儿提供依据。方法将河南省南阳市中心医院2022年6月至2023年3月收治的105例癫痫患儿根据用药不同分为对照组(52例)与试验组(53例),对照组进行双歧杆菌乳杆菌三联活菌片口服治疗,试验组进行左乙拉西坦联合双歧杆菌乳杆菌三联活菌片口服治疗,治疗周期为3个月。对比2组临床效果,治疗前后α波、β波、θ波数量、癫痫样放电量、语言智商、总智商、操作智商评分、免疫球蛋白G、免疫球蛋白A、免疫球蛋白M水平。结果经过临床治疗3个月后试验组的临床有效率为92%(41/52),相较于对照组的79%(49/53)升高;治疗后2组与治疗前相比α波、β波、θ波数量、癫痫样放电数量均降低,试验组相较于对照组降低;治疗后2组与治疗前比语言智商、总智商、操作智商评分及免疫球蛋白G、免疫球蛋白A、免疫球蛋白M水平均升高,试验组相较于对照组升高,差异有统计学意义(P<0.05)。结论采用左乙拉西坦联合双歧杆菌乳杆菌三联活菌片治疗癫痫患儿可提高临床疗效,控制患儿脑电活动,改善认知功能,提高患儿免疫功能,促进患儿康复,可供临床治疗癫痫患儿参考。 展开更多
关键词 癫痫 左乙拉西坦 双歧杆菌乳杆菌三联活菌片 认知功能 细胞免疫
下载PDF
左乙拉西坦片结合丙戊酸钠缓释片对癫痫患者血清神经递质水平、癫痫发作情况的影响
17
作者 高媛媛 《反射疗法与康复医学》 2023年第22期131-134,共4页
目的探究左乙拉西坦片结合丙戊酸钠缓释片对癫痫患者血清神经递质水平、癫痫发作情况的影响。方法选择2021年3月—2023年3月我院收治的68例癫痫患者为研究对象,按随机数字表法将其分为对照组和观察组,每组34例。两组患者均给予禁烟禁酒... 目的探究左乙拉西坦片结合丙戊酸钠缓释片对癫痫患者血清神经递质水平、癫痫发作情况的影响。方法选择2021年3月—2023年3月我院收治的68例癫痫患者为研究对象,按随机数字表法将其分为对照组和观察组,每组34例。两组患者均给予禁烟禁酒、健康饮食、规律作息等一般治疗,对照组在一般治疗基础上给予患者丙戊酸钠缓释片,观察组在对照组基础上给予患者左乙拉西坦片。对比两组患者血清神经递质水平、癫痫发作情况和不良反应发生情况。结果治疗后,观察组miR-134-5p相对表达量(1.53±0.46)、脑源性神经营养因子水平(17.43±3.22)ng/L均低于对照组的(2.02±0.64)、(22.82±3.16)ng/L,观察组多巴胺(9.94±2.53)ng/L和5-羟色胺水平(69.45±11.26)ng/L均高于对照组的(7.92±1.87)ng/L、(62.37±10.66)ng/L,组间差异有统计学意义(P<0.05)。治疗后,观察组癫痫发作次数(0.34±0.05)次/年少于对照组的(1.52±0.50)次/年,观察组发作持续时间(2.16±0.54)min/次低于对照组的(3.65±0.72)min/次,组间差异有统计学意义(P<0.05)。两组不良反应发生情况对比,组间差异无统计学意义(P>0.05)。结论左乙拉西坦片联合丙戊酸钠缓释片治疗癫痫患者,有助于癫痫发作情况的改善,还可调节血清神经递质水平,且安全性较高,值得推广。 展开更多
关键词 癫痫 左乙拉西坦片 丙戊酸钠缓释片 血清神经递质水平 癫痫发作情况
下载PDF
左乙拉西坦片联合小儿抗痫胶囊对儿童癫痫症状发作、脑电图的影响
18
作者 吴春美 《中外医药研究》 2023年第6期73-75,共3页
目的:分析左乙拉西坦片联合小儿抗痫胶囊治疗对儿童癫痫症状发作、脑电图的影响。方法:选取2022年9月—2023年1月鄄城县人民医院收治的癫痫患儿70例作为研究对象,根据随机数字表法分成单一组与联合组,各35例。单一组口服左乙拉西坦片治... 目的:分析左乙拉西坦片联合小儿抗痫胶囊治疗对儿童癫痫症状发作、脑电图的影响。方法:选取2022年9月—2023年1月鄄城县人民医院收治的癫痫患儿70例作为研究对象,根据随机数字表法分成单一组与联合组,各35例。单一组口服左乙拉西坦片治疗,联合组在单一组基础上应用小儿抗痫胶囊治疗。比较两组中医证候积分、癫痫发作情况、动态脑电图监测结果、生活质量评分以及不良反应情况。结果:单一组主证积分、兼证积分以及总积分均高于联合组,差异有统计学意义(P<0.001);治疗后,两组癫痫发作频率、持续时间均改善,且联合组优于单一组,差异有统计学意义(P<0.05);治疗后,两组痫性放电以及总异常发生率均降低,且联合组低于单一组,差异有统计学意义(P<0.05);两组生理领域、心理领域评分均升高,且联合组评分高于单一组,差异有统计学意义(P<0.05)。结论:左乙拉西坦片与小儿抗痫胶囊联合使用,能够有效提高患儿的治疗效果,改善其脑部异常放电,降低癫痫发作的次数,缩短持续时间,提高患儿的生活质量,且两种药物联用不会增加不良反应发生率。 展开更多
关键词 儿童癫痫 左乙拉西坦片 小儿抗痫胶囊 生活质量 不良反应
下载PDF
手性拆分左乙拉西坦片中的右旋体 被引量:5
19
作者 李丹 李晓宁 李春红 《中国药事》 CAS 2009年第7期643-646,共4页
目的采用高效液相色谱法手性拆分左乙拉西坦片中的右旋异构体。方法采用CHIRALPAK AD-H色谱柱;以正己烷-异丙醇(80∶20)为流动相,检测波长为220nm,流速为1.0mL.min-1。结果在此色谱条件下,消旋体的分离可在10min内完成,分离度为5.90,右... 目的采用高效液相色谱法手性拆分左乙拉西坦片中的右旋异构体。方法采用CHIRALPAK AD-H色谱柱;以正己烷-异丙醇(80∶20)为流动相,检测波长为220nm,流速为1.0mL.min-1。结果在此色谱条件下,消旋体的分离可在10min内完成,分离度为5.90,右旋异构体的检测限可达4.1120×10-6μg.L-1。结论此方法可对左乙拉西坦片中的右旋异构体进行定量分析。 展开更多
关键词 左乙拉西坦片 HPLC 右旋体 手性分离
下载PDF
坦度螺酮联合左乙拉西坦片对癫痫患者S-100β、hs-CRP、MDA水平的影响 被引量:2
20
作者 孙晓静 肖悠美 +1 位作者 张存玲 袁学谦 《临床医学工程》 2021年第3期341-342,共2页
目的探讨坦度螺酮联合左乙拉西坦片对癫痫患者S-100β蛋白(S-100β)、超敏C-反应蛋白(hs-CRP)、丙二醛(MDA)水平的影响。方法将2018年4月至2020年4月我院收治的118例癫痫患者随机分为单药组和联合组。单药组口服左乙拉西坦片进行治疗,... 目的探讨坦度螺酮联合左乙拉西坦片对癫痫患者S-100β蛋白(S-100β)、超敏C-反应蛋白(hs-CRP)、丙二醛(MDA)水平的影响。方法将2018年4月至2020年4月我院收治的118例癫痫患者随机分为单药组和联合组。单药组口服左乙拉西坦片进行治疗,联合组在单药组基础上口服坦度螺酮胶囊进行治疗。比较两组患者的临床疗效、不良反应发生情况、心理状况和S-100β、 hs-CRP、 MDA水平。结果联合组的总有效率为96.61%,高于单药组的77.97%(P <0.05)。治疗后,联合组的HAMA-14、 HAMD-17评分低于单药组(P <0.05)。治疗后,联合组的S-100β、 hs-CRP、 MDA水平低于单药组(P <0.05)。单药组的不良反应发生率为3.39%,与联合组的5.08%比较无统计学差异(P>0.05)。结论坦度螺酮联合左乙拉西坦片治疗癫痫患者效果较佳,可明显改善患者的心理状况,降低S-100β、 hs-CRP、 MDA水平,且安全性较高。 展开更多
关键词 坦度螺酮 左乙拉西坦片 癫痫 S-100Β HS-CRP MDA
下载PDF
上一页 1 2 3 下一页 到第
使用帮助 返回顶部